Bromojimscaline

Bromojimscaline
Clinical data
Other namesBromojimscalin; 7-Bromojimscaline
Drug classSerotonin receptor modulator; Serotonin 5-HT2 receptor modulator
ATC code
  • None
Identifiers
  • 1-(7-bromo-4,5,6-trimethoxy-2,3-dihydro-1H-inden-1-yl)methanamine
Chemical and physical data
FormulaC13H18BrNO3
Molar mass316.195 g·mol−1
3D model (JSmol)
  • NCC1CCc2c1c(Br)c(OC)c(c2OC)OC
  • InChI=1S/C13H18BrNO3/c1-16-11-8-5-4-7(6-15)9(8)10(14)12(17-2)13(11)18-3/h7H,4-6,15H2,1-3H3
  • Key:ZUNQYKNYHGWYLR-UHFFFAOYSA-N

Bromojimscaline, or 7-bromojimscaline, is a serotonin 5-HT2 receptor modulator of the phenethylamine and scaline families related to 2CB-Ind. It is the 7-bromo derivative of jimscaline, a cyclized phenethylamine analogue of mescaline with a 1-aminomethylindane structure. Bromojimscaline shows 1.6- and 4.2-fold higher affinities for the serotonin 5-HT2A and 5-HT2C receptors, respectively, than jimscaline. It also shows high affinity for the serotonin 5-HT1A receptor. The drug was developed by David E. Nichols and colleagues at Purdue University and was subsequently reported by Daniel Trachsel in 2013, who obtained the information via personal communication with Nichols in 2010. It is not a controlled substance in Canada as of 2025.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.